Dosage research on KLOW Blend

Preclinical research dose ranges

In published preclinical research on the individual components, KPV rodent dose ranges in colitis and dermatitis models have most commonly fallen in the 5 to 100 microgram per dose range. GHK-Cu in-vivo dose ranges have most commonly fallen in the 0.5 to 5 milligram per kilogram range subcutaneously for systemic endpoints. BPC-157 rodent dose ranges have most commonly fallen in the 1 to 10 microgram per kilogram range. TB-500 / thymosin beta-4 rodent dose ranges have most commonly fallen in the 6 to 24 milligrams per kilogram range for systemic endpoints.

No published combined-administration pharmacology study of the four components in this fixed-ratio formulation has appeared in the indexed research literature. The stacking convention extends the Glow Blend’s three-component dermal-and-soft-tissue framing with KPV as the anti-inflammatory addition. The rationale is broad-spectrum inflammation-plus-tissue-remodeling research applications rather than mechanism-specific endpoint isolation.

The Ronin catalog supplies the blend at a 10:50:10:10 mass ratio (KPV + GHK-Cu + BPC-157 + TB-500). The 50 mg GHK-Cu loading reflects the higher published per-dose mass conventions for GHK-Cu relative to the other three components. Investigators interested in per-component contributions or precise per-component dose matching would need separate single-compound vials rather than the pre-combined KLOW Blend formulation.

Dose-response considerations from the published literature

The per-component published literatures have reported dose-response characteristics described in the individual KPV, GHK-Cu, BPC-157, and TB-500 dosage research pages. No combined-administration dose-response curve for the KLOW Blend formulation has appeared in the indexed published research literature.

No Phase 1 or Phase 2 dose-ranging trial of the combined four-component blend has appeared in the indexed clinical-trial literature at the time of writing. The research community continues to rely on the per-component literatures for dose-design inference.

Reconstitution math and per-vial dose calculation

An 80 mg lyophilised KLOW Blend vial (10 mg KPV + 50 mg GHK-Cu + 10 mg BPC-157 + 10 mg TB-500) reconstituted with 2 mL of bacteriostatic water yields a stock concentration of 40 mg per mL of combined formulation (5 mg per mL KPV + 25 mg per mL GHK-Cu + 5 mg per mL BPC-157 + 5 mg per mL TB-500). From this stock, a research aliquot of 0.1 mL contains 4 mg of combined formulation. Researchers working with the per-component dose ranges further dilute the stock to a working concentration appropriate to the model. Refrigerated storage at 2 to 8 degrees Celsius, protected from light, is the standard handling practice for all four components; the GHK-Cu component additionally requires protection from oxidising conditions to preserve the copper-bound form.

Research-protocol design considerations

Protocol-design choices in research using the KLOW Blend reflect several recurring considerations. The fixed-ratio four-component formulation is the central protocol-design decision: investigators interested in per-component contributions would need separate single-compound vials.

The per-component dose-range mismatch across the four components (KPV at microgram-per-dose, GHK-Cu at sub-milligram-per-kilogram, BPC-157 at microgram-per-kilogram, TB-500 at milligram-per-kilogram) is a consideration in the design rationale for the 10:50:10:10 mass-ratio formulation. The blend’s per-dose mass amounts are mismatched against the published per-component dose-equivalent ranges in different directions for each component.

The KLOW Blend distinguishes the format from Glow Blend (which lacks KPV) for researchers who want the anti-inflammatory addition to the three-component dermal-and-soft-tissue framing. The copper-bound GHK-Cu complexation state remains the binding handling constraint on the blend’s storage.

References

1. Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 2008. [PMID 18054561]
2. Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science Polymer Edition, 2008. [PMID 18644225]
3. Pickart L et al. The human tripeptide GHK-Cu in prevention of oxidative stress. Oxidative Medicine and Cellular Longevity, 2012. [PMID 22666519]
4. Sikiric P et al. Stable gastric pentadecapeptide BPC 157 in the treatment of colitis and ischemia. World Journal of Gastroenterology, 2024. [PMID 39325560]
5. Malinda KM et al. Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB Journal, 1997. [PMID 9194528]